Vedanta Biosciences said it significantly reduced staff to concentrate remaining resources on its lead live‑biotherapeutic candidate VE303, now positioned for a Phase 3 study in recurrent Clostridioides difficile infection scheduled to complete by June 2027. Reports indicate large layoffs and furloughs as the company narrows its pipeline after other programs failed to meet endpoints. Vedanta framed the restructuring as a strategic refocus following a failed phase 2 for an Enterobacteriaceae‑targeted program and prior financing rounds. The move mirrors capital‑allocation decisions across microbiome biotechs moving toward single‑asset execution after high cash burn and development setbacks. The company pointed to Phase 2 data supporting VE303 as rationale; investors and potential acquirers will watch for trial enrollment, funding needs and regulatory interactions given the crowded space after Seres’ Vowst approval.